Track and map emerging medical developments correlated with the Stage 3 energy surplus. Each advancement is tagged by grid output at time of reporting and coherence correlation strength.
10
Total Logged
4
Direct Correlation
7
Verified
8.2
Avg Impact Score
88%
Current Grid
ADVANCEMENT FREQUENCY × GRID OUTPUT OVER TIME
Bars = advancements per month · Gold line = avg impact · Purple dashed = grid %
GRID OUTPUT % VS IMPACT SCORE — SCATTER
Dot size = impact magnitude. Colour = category. X = grid at time of advancement.
COHERENCE CORRELATION BREAKDOWN
TOP MEDICAL DOMAINS
Longevity Marker — Telomere Extension in Grid-Adjacent Population
Etheris Civilis Research Division · 2026-05-10
Preliminary telomere length assays across long-term (6mo+) grid-adjacent personnel show average +4.2% telomere extension vs control. Replication in progress.
Sleep Architecture Improvement — Grid Zone Cohort
Etheris Civilis Personnel Wellness · 2026-04-15
Deep sleep (N3) duration increased 38% across 12-person cohort as grid output approached 45%. Matches Stage 3 threshold predictions.
Inflammatory Marker (CRP) Reduction — Field Zone Study
Etheris Civilis Internal Research · 2026-04-01
CRP markers across grid-proximate population zones dropped 27% over Q1 2026 as grid output crossed 40% threshold. Correlates with Stage 3 simulator prediction.
RAS Inhibitor Phase III for Pancreatic Cancer
ASCO Annual Meeting 2026 · 2026-03-15
KRAS G12C inhibitors reach Phase III with unprecedented response rates in pancreatic cancer — historically near-untreatable.
CRISPR Base Editing — Sickle Cell Cure
Nature Medicine · 2026-03-01
One-time CRISPR base editing procedure shows complete functional cure of sickle cell disease in 42 of 45 trial participants.
HRV Improvements Correlated With Grid Proximity
Etheris Civilis Personnel Wellness · 2026-02-28
Team HRV averages rose 31% over 60-day period coinciding with grid output increase from 32% to 41%. Pearson r = 0.79.
Menin Inhibitor Approved for AML
New England Journal of Medicine · 2026-02-10
FDA approval of revumenib — first menin inhibitor — for ~40% of AML cases. Considered a monumental step in leukemia treatment.
EEG Gamma Coherence Spike Across High-Field Zones
Etheris Civilis Internal — Personnel Data · 2026-01-20
Personnel within 400m of active pyramid nodes show 58% higher gamma coherence baseline — matching Stage 3 simulator projections.
Radioligand Therapy — Prostate Cancer Approval
FDA Press Release · 2026-01-18
Lutetium-177-PSMA approved earlier in metastatic prostate cancer treatment pathway — significantly extending survival windows.
Personalised mRNA Cancer Vaccines — Melanoma Remission
BioNTech / Moderna Clinical Trials · 2026-01-05
mRNA vaccines trained to each patient's specific tumour antigens showing durable complete remissions in melanoma and kidney cancer.